Activity landscape of DNA methyltransferase inhibitors bridges chemoinformatics with epigenetic drug discovery

被引:18
|
作者
Jesus Naveja, J. [1 ,2 ]
Medina-Franco, Jose L. [1 ]
机构
[1] Univ Nacl Autonoma Mexico, Dept Farm, Fac Quim, Mexico City 04510, DF, Mexico
[2] Univ Nacl Autonoma Mexico, PECEM, Fac Med, Mexico City 04510, DF, Mexico
关键词
activity cliffs; cancer; data mining; DNA methyltransferase; epi-informatics; structure-activity relationships; CONSENSUS-ACTIVITY-CLIFFS; CANCER; METHYLATION; SIMILARITY; TARGETS; PREDICTION; DOCKING; MAPS;
D O I
10.1517/17460441.2015.1073257
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Introduction: Activity landscapes are valuable tools for exploring systematically the structure-activity relationships (SAR) of chemical databases. Their application to analyze the SAR of DNA methyltransferase (DNMT) inhibitors, which are attractive compounds as potential epi-drugs or epi-probes, provides useful information to identify pharmacophoric regions and plan the development of predictive models and virtual screening. Areas covered: This paper highlights different approaches for conducting SAR analysis of datasets with a particular focus on the activity landscape methodology. SAR information of DNMT inhibitors (DNMTi), stored in a public database, is surveyed to further illustrate concepts and generalities of activity landscape modeling with a special emphasis on structure-activity similarity (SAS) maps. Expert opinion: The increasing SAR information reported for DNMTi opens up avenues to implement activity landscape methods. Despite several activity landscape methods, such as SAS maps, being well established, these need further refinement. For instance, novel combinations of multiple representations, such as the addition of Z-values of similarity (fusion-Z), lead to more robust representations of consensus SAS maps. Density SAS maps improve the visualization of the SAR. A survey of activity cliffs (i.e., pairs of compounds with high structural similarity but high differences in potency) of DNMTi available in a public database suggest that it is feasible to develop predictive models for non-nucleoside DNMTi using approaches such as quantitative structure-activity relationships and that non-nucleoside DNMTi in ChEMBL can be used as query molecules in similarity-based virtual screening.
引用
收藏
页码:1059 / 1070
页数:12
相关论文
共 50 条
  • [31] Epigenetic targets and drug discovery Part 2: Histone demethylation and DNA methylation
    Liu, Ke
    Liu, Yanli
    Lau, Johnathan L.
    Min, Jinrong
    PHARMACOLOGY & THERAPEUTICS, 2015, 151 : 121 - 140
  • [32] PDE10A inhibitors: An assessment of the current CNS drug discovery landscape
    Chappie, Tom
    Humphrey, John
    Menniti, Frank
    Schmidt, Chris
    CURRENT OPINION IN DRUG DISCOVERY & DEVELOPMENT, 2009, 12 (04) : 458 - 467
  • [33] The genetic and epigenetic landscape for CNS drug discovery targeting cross-diagnostic behavioral domains
    de Mooij-van Malsen, Annetrude
    Pjetri, Eneda
    Kas, Martien J.
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2015, 753 : 135 - 139
  • [34] Direct monitoring of breast and endometrial cancer cell epigenetic response to DNA methyltransferase and histone deacetylase inhibitors
    Teixeira, S. R.
    Abreu, C. M.
    Parkes, L.
    Davies, J.
    Yao, S.
    Sawhney, M. A.
    Margarit, L.
    Gonzalez, D.
    Mendes Pinto, I.
    Francis, L. W.
    Conlan, R. S.
    BIOSENSORS & BIOELECTRONICS, 2019, 141
  • [35] DNMT (DNA methyltransferase) inhibitors radiosensitize human cancer cells by suppressing DNA repair activity
    HakJae Kim
    JinHo Kim
    EuiKyu Chie
    Park DaYoung
    InAh Kim
    IlHan Kim
    Radiation Oncology, 7
  • [36] DNMT (DNA methyltransferase) inhibitors radiosensitize human cancer cells by suppressing DNA repair activity
    Kim, Hak Jae
    Kim, Jin Ho
    Chie, Eui Kyu
    Young, Park Da
    Kim, In Ah
    Kim, Il Han
    RADIATION ONCOLOGY, 2012, 7
  • [37] The landscape of drug discovery in atherosclerosis and dyslipidaemia revisited: an update of patenting activity
    Suckling, Keith
    EXPERT OPINION ON THERAPEUTIC PATENTS, 2012, 22 (03) : 199 - 204
  • [38] The landscape of drug discovery in atherosclerosis and dyslipidaemia: a survey from patenting activity
    Suckling, Keith
    EXPERT OPINION ON THERAPEUTIC PATENTS, 2008, 18 (05) : 473 - 484
  • [39] Structure based drug discovery and in vitro activity testing for DNA gyrase inhibitors of Salmonella enterica serovar Typhi
    Sharma, Priyanka
    Kumar, Manoj
    Dahiya, Sushila
    Sood, Seema
    Das, Bimal Kumar
    Kaur, Punit
    Kapil, Arti
    BIOORGANIC CHEMISTRY, 2020, 104
  • [40] Epigenetic Drug Discovery: Targeting DNA Methyltransferases (vol 17, pg 2, 2012)
    Foulks, J. M.
    Parnell, K. M.
    Chau, S.
    Swierczek, K.
    Saunders, M.
    Wright, K.
    Hendrickson, T. F.
    McCullar, M., V
    Kanner, S. B.
    JOURNAL OF BIOMOLECULAR SCREENING, 2012, 17 (05) : 700 - 700